Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Anterios On Deck For Ipo - Anterios (pending:ante) | Seeking Alpha

ETF Hub Anterios on deck for IPO May 4 2015, 13:09 ET | About: Anterios (ANTE) | By: Douglas W. House , SA News Editor New http://sweatingblog.info/how-to-control-body-sweating/ York, NY-based Anterios (Pending: ANTE ) is set for its IPO of 3.9M shares of common stock at $12 - 14. The clinical stage biopharmaceutical firm develops botulinum products for therapeutic and aesthetic applications. Botulinum toxin type A (botulinum) is currently almost a $3B global market, led by Allergan's ( AGN ) Botox. The firm's lead product candidate http://sweatingblog.info/does-sweating-help-cure-colds/ is the Phase 2-stage ANT-1207 , a topical formulation of botulinum for the treatment of primary axillary hyperhidrosis (excessive underarm sweating), facial acne and lateral canthal lines (crow's feet wrinkles). Its second candidate is AI-09, an injectable botulinum that will be packaged as a ready-to-use liquid. Currently available injectable botulinum products are lyophilized which require reconstitution prior to use.
For the original version including any supplementary gustatory sweating images or video, visit http://seekingalpha.com/news/2482986-anterios-on-deck-for-ipo?source=feed_news_all

Don't be the product, buy the product!